Xiao-fang F. Guo

601 Jinsui Road
Xinxiang, 453003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy.

A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy.

Journal: Journal of drug targeting

Published: July 28, 2021

Combination of Berberine with Resveratrol Improves the Lipid-Lowering Efficacy.

Combination of Berberine with Resveratrol Improves the Lipid-Lowering Efficacy.

Journal: International journal of molecular sciences

Published: September 28, 2018

Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.

Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.

Journal: Cancer chemotherapy and pharmacology

Published: February 06, 2018

A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.

A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.

Journal: Oncology reports

Published: September 23, 2016

A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.

A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.

Journal: Oncotarget

Published: July 04, 2016

An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.

An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.

Journal: PloS one

Published: November 29, 2013

Mechanism of MBL inhibiting the LPS-induced DC maturation

Mechanism of MBL inhibiting the LPS-induced DC maturation

Journal: Zhongguo shi yan xue ye xue za zhi

Published: July 03, 2013

Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy.

Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy.

Journal: Oncology letters

Published: October 16, 2012

Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.

Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.

Journal: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

Published: March 31, 2012

Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.

Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.

Journal: Oncology reports

Published: September 11, 2011

Showing 1-10 of 10

Last Updated: 09/26/2026